Sarcopenia affects up to 16% of the world’s aging population and is one of the leading factors in the loss of independence. Marked by a loss of both muscle mass and function or strength, it’s behind ...

Amber Therapeutics Ltd. revealed positive data from the first-in-human investigation of its Amber-UI device, an implantable closed-loop bioelectrical therapy for urinary incontinence. Initial results ...

Key initial results from AURA-2 study highlight good safety and scalability of Amber-UI therapy A strong efficacy signal was seen in the form of complete resolution of incontinence episodes six months ...